Connect with us

Hi, what are you looking for?

Stock

Morgan Stanley upgrades Vir Biotechnology to ‘overweight,’ raises PT to $20

Investing.com — Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an “overweight” rating, shifting from “equal-weight,” and have also increased their price target to $20 from $10.

The analysts flagged promising preliminary data from the company’s dual-masked TCE therapies. Vir-5500, targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer, demonstrated notable safety and efficacy in early trials.

Among heavily pretreated participants, a 58% PSA50 response rate was observed, signaling a reduction in prostate-specific antigen levels.

Another candidate, Vir-5818, showed early signs of efficacy in colorectal cancers, with partial tumor shrinkage in 33% of the treated cases. Both drugs exhibited manageable safety profiles, with no high-grade toxicities reported.

As per Morgan Stanley, the dual-masking technology offered by Vir can enhance therapeutic tolerability and efficacy, making these treatments more acceptable to earlier stages of cancer treatment.

Additionally, the analysts noted that the company has extended its cash runway to mid-2027, enhancing its ability to fund ongoing clinical trials and explore strategic partnerships.

This upgrade comes as Vir diversifies beyond its traditional infectious disease portfolio into oncology.

While the company has deprioritized some programs, such as hepatitis B, the focus on innovative cancer treatments aligns with its focus on high-potential areas.

This post appeared first on investing.com

    You May Also Like

    Latest News

    A group of more than 60 former Democratic and Republican attorneys general sent a new letter to Senate leaders Thursday urging the confirmation of...

    Stock

    Investing.com — RBC Capital Markets in a note dated Thursday has downgraded Swatch Group (SIX:UHR) to an “underperform” rating, citing structural and cyclical challenges...

    Stock

    Investing.com — Universal Music Group (AS:UMG) and Spotify (NYSE:SPOT) have announced a new multi-year deal for recorded music and publishing, the companies announced in...

    Stock

    By Rocky Swift TOKYO (Reuters) -Japan’s Fuji Media said on Monday its chairman and the head of its TV unit would step down immediately...



    Disclaimer: Techreportdiversity.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 Techreportdiversity.com